Leukemia & Lymphoma

Papers
(The H4-Index of Leukemia & Lymphoma is 18. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
The prognostic role of gene polymorphisms in patients with indolent non-Hodgkin lymphomas and mantle-cell lymphoma receiving bendamustine and rituximab: results of the 5-year follow-up study44
Impact of SF3B1 mutation in myelofibrosis37
Ruxolitinib bridging therapy to allogeneic SCT for high-risk refractory subcutaneous panniculitis-like T-cell lymphoma36
Pulmonary infections in patients with acute myeloid leukemia receiving frontline treatment with hypomethylating agents27
Successful treatment with bortezomib, thalidomide and dexamethasone in plasma cell myeloma post-bone marrow transplant27
Cytogenetic abnormalities in NPM1-mutated acute myeloid leukemia25
CD274 structural variants for guiding treatment with PD-1 blockade in a patient with relapsed/refractory chronic active EBV transformed to NK lymphoma23
The mechanism of action, pharmacological characteristics, and clinical utility of the amyloid depleter birtamimab for the potential treatment of AL amyloidosis23
The effect of the plasma methotrexate concentration during high-dose methotrexate therapy in childhood acute lymphoblastic leukemia23
Efficacy and safety of voriconazole as invasive fungal infection prophylaxis in patients with acute myeloid leukemia23
Carfilzomib in combination with R-CHOP for initial treatment of patients with non-germinal center diffuse large B-cell lymphoma: a multicenter, single arm, phase 1/2 study22
Progressive multifocal leukoencephalopathy post ibrutinib therapy in relapsed chronic lymphocytic leukaemia21
Dupilumab for the treatment of refractory lenalidomide rash in patients with multiple myeloma21
Evaluating early response assessment in extranodal natural killer/T-cell lymphoma by analyzing ΔSUVlbm between baseline and interim 18 F-FDG PET/CT scans21
Treatment outcomes of venetoclax-combination regimens for relapsed/refractory myeloid malignancies after anti-CD47-directed therapy20
Organ toxicities associated with chimeric antigen receptor T-cell therapy20
Blinatumomab for the treatment of acute lymphoblastic leukemia in a real-world setting: clinical vignettes19
XX International workshop on chronic lymphocytic leukemia19
Matching-adjusted indirect comparison of axi-cel and liso-cel in relapsed or refractory large B-cell lymphoma18
Risk factors for mortality and re-admission of children with hematological malignancies to the intensive care unit due to sepsis18
0.0818190574646